Ann: Clinical Trial Preliminary Outcomes, page-141

Just some very basics for new comers:

Fully paid ordinary shares
No escrow: 59,548,054
Escrowed for 24 months from date of quotation: 28,487,058
Total Shares on issue: 88,035,112

Last Top 20 - 56.8%
50,092,921 (19,740,889 held by creator Dr Trevisan)

As you can see there is not much free float.  Hartley's have 8m of the 59,548.054 on offer, and expect the top 20 to be holding most of there shares

FDA

Emergo appointed to assist with FDA submission under 501(k).  Once the full results of the study are produced, they will be used as part of the submission.  

Distributor Agreements

The company strategy has been to target Europe first, as they already have CE mark, as well as TGA registration in Australia.  The target market is 140k devices.  I think they make around $1000 per device.  They have distributor agreements in the following countries:

- Italy
- Australia
- Greece
- Turkey
- Germany and Switzerland
- Austria
- Saudi Arabia

R & D grant

The company should be assisted in the future with a rebate for R & D, which will provide additional capital

Anyway, just a few pointers for those that have just been introduced to this stock